Viaderma Inc (OTCMKTS:VDRM) a specialty pharmaceutical firm devoted to getting new products to industry reported the Patent Pending application of its unique transdermal mechanism for the delivery of Calanoids and Tetrahydrocannabinol for the cure of numerous diseases. The transdermal system can offer through topical skin immersion to localized regions and straight into the blood stream.

The highlights

The Patent application utilizing the combination of THC and CBD with the delivery plan was submitted in 2014. This system can deliver nutrients and medications into the body via skin. For instance, an individual with a migraine headache can put the THC and CBD blended with the delivery compound and put to the neck with instant absorption into the bloodstream via the corroded artery. ViaDerma is in the clinical testing phases of an anti-aging topical offering, topical pain drug, a topical for male-pattern hairlessness, and a topical intended to increase male libido.

Earlier in November, recreational and medical marijuana was approved in numerous states that voted on pot marijuana provisions, which is becoming the biggest electoral win for marijuana reforms after 2012. The application of CBD’s is recognized for the cure of inflammation and other several diseases, such as, fibromyalgia, Cohn’s disease, nicotine addiction, migraine headaches, schizophrenia, and pain management for Multiple Sclerosis and cancer.

ViaDerma has Viabecline, which is a topical fluid tetracycline-based antibiotic that utilizes a patent-pending unique transdermal delivery plan that can convert oral drug active ingredients into topical medications. The drug is approved by FDA as a first aid drug to aid prevent skin infection in scrapes, burns and minor cuts, but prominently, has demonstrated to be effective in combating more dangerous types of staphylococcus aureus infections. Without the launch of unique antibiotic regimen, infections can spread and at times turn out to be life threatening.

ViaDerma finds the application of CBD’s along with Proprietary transdermal delivery plan for the cure and continuing trials look extremely promising and shows efficacy in terms of curing numerous unrelated diseases.